

Investor Relations Brief

6

2026

June



Molecular Diagnostics: ExiPrep™ 16Dx Wins UNICEF Tender in Mongolia

In April, Bioneer was selected as the supplier of its automated nucleic acid extraction system ExiPrep™ 16Dx through a tender run by UNICEF, marking its entry into Mongolia's public healthcare market. The specific supply terms and contract size are confidential under the agreement; this material is intended only as a general description of the facts. The company completed delivery and installation at Mongolia's National Center for Zoonotic Diseases (NCZD), under the Ministry of Health, and the National Cancer Center, reaffirming its product's reliability and applicability in overseas public procurement markets.

This supply is significant as a case of Bioneer's automated nucleic acid extraction solution being adopted by major public healthcare institutions in Mongolia. In particular, this reference of winning a contract through an international organization's tender is expected to strengthen the company's credibility as it expands overseas public procurement business and enters new countries.

ExiPrep™ 16Dx automates the entire nucleic acid extraction process, which was previously largely manual, using Bioneer's proprietary nano-bead technology to deliver strong extraction performance and a simple workflow. This can improve testing efficiency and result consistency, and the system has been well regarded for its usefulness in public healthcare institutions and molecular diagnostic testing settings. Following the equipment supply, Bioneer invited Mongolian users to its headquarters for hands-on training from May 13–15, covering equipment operation, testing procedures, and various applications — strengthening local users' operational capabilities and supporting stable, ongoing use of the equipment.

During the training, the point-of-care multiplex system IRON-qPCR™ and the fully automated system ExiStation™ FA 96 were also introduced. Attendees showed strong interest in the systems' ease of use, level of automation, and diagnostic accuracy, and Bioneer plans to continue exploring additional equipment supply and new installations with its Mongolian partners based on this response. An NCZD official who attended the training expressed high satisfaction with the convenience and extraction performance of the already-installed ExiPrep™ 16Dx, and assessed that ExiStation™ FA 96 and IRON-qPCR™ also hold strong potential for use in Mongolia's field diagnostic settings.

Starting with this entry into Mongolia's public healthcare market, Bioneer plans to further strengthen its presence in overseas public procurement markets, building on its accumulated technology and growing global reference base. A Molecular Diagnostics Division official said, "To become a global molecular diagnostics platform company, we will keep building not only technological innovation and quality competitiveness but also references recognized in real-world settings, driving sustainable growth and raising corporate value."




Business Updates

Molecular Diagnostics: IRON-qPCR™ TB Data From Kazakhstan

On April 30, at the international conference "Innovations and Medical Technologies — The Path to Public Health Improvement" in Almaty, Kazakhstan, Bioneer presented performance evaluation results for tuberculosis detection using its IRON-qPCR™ molecular diagnostic platform, once again highlighting its applicability and technical competitiveness in public health settings. The conference, focused on international medicine and public health, drew more than 200 experts, including Kazakh health professionals, a WHO Europe TB Advisor, and representatives from a German tuberculosis research center.

Dr. Adilova Gushem, head of the clinical and bacteriology testing center at the Almaty Public Health Department's central branch, presented "Evaluation of the Performance of IRON-qPCR™ RFIA in Detecting Tuberculosis," covering clinical performance results from testing conducted at the Almaty center. Dr. Gushem emphasized that Bioneer's IRON-qPCR™ RFIA TB diagnostic not only performs well on accuracy but also stands out by rapidly detecting both multidrug-resistant and extensively drug-resistant tuberculosis in a single test. She also praised IRON-qPCR™'s improved testing speed, simplified workflow, and lab-floor efficiency and usability compared with conventional diagnostic methods.

As an evaluation led by a public health institution, this result is meaningful as an indicator of the product's reliability and field applicability. However, since it was conducted at a specific institution under specific conditions, the same results may not be reproducible in every testing environment, and the product's scope of use may vary depending on regulatory approval status in each country.



Business Updates

Molecular Diagnostics: IRON-qPCR™ TB Data From Kazakhstan

Prior to that, on April 29, Kazakhstan's National Scientific Center of Dermatology and Infectious Diseases (KSCDID) hosted a molecular diagnostics seminar and hands-on training for directors and lab specialists from 15 local AIDS centers. The training introduced both the IRON-qPCR™ system and the fully automated ExiStation™ FA, along with education on Bioneer's molecular diagnostic solutions for HIV, hepatitis, respiratory viruses, sexually transmitted infections, and other conditions. Participants who worked directly with Bioneer's systems responded positively to their result reliability and ease of operation. They also showed strong interest in ExiStation™ FA, which automatically handles everything from tube opening to nucleic acid extraction and PCR testing once a sample tube is loaded, citing its full automation and high throughput as key strengths for rapid mass testing.

A Bioneer official said, "This event went beyond a simple product introduction, showing that Bioneer can help standardize and improve the operational efficiency of Central Asia's public health diagnostic systems. We will continue building on this meaningful progress as we expand into overseas diagnostic markets and strengthen brand trust."



Life Sciences: At KBMS 2026

Bioneer showcased solutions and equipment for mRNA-based gene expression analysis at the 2026 Korean Basic Medical Sciences (KBMS) conference, held April 29–30 at DCC in Daejeon. KBMS is an academic event where researchers in basic medicine and life sciences share the latest findings and technologies, and this year's event drew experts and industry representatives from a range of research fields.

Bioneer centered its presentation on the gene expression analysis workflow from mRNA extraction through cDNA synthesis to real-time PCR, showcasing the extraction reagent EcoQprep™, the automated extraction system ExiPrep™ 96 Lite, the real-time PCR system ExiCycler™ V5, and related reagents. The EcoQprep™ mRNA Kit, which enables fast, simple mRNA extraction without centrifugation, and ExiCycler™ V5, with its ramping rate of up to 10.0°C/sec, drew particular interest from researchers working in gene expression analysis.

Chairman Han-Oh Park also gave a conference presentation titled "SAMiRNA®: A Rapid-Development Platform for Respiratory Antiviral Therapeutics in Pandemic Response," sharing Bioneer's research capabilities and vision for pandemic-response technology and RNA-based therapeutic development.

The conference let Bioneer engage directly with researchers in basic medicine and life sciences, gaining insight into field needs and the latest research trends that will inform future product development and marketing strategy. Bioneer will continue expanding its high-quality research solutions and next-generation biotech development to meet the evolving needs of researchers.



Business Updates

Life Sciences: At KBCS 2026 Spring Meeting

Bioneer showcased its research solutions and products at the 2026 Korean BioChip Society (KBCS) Spring Meeting, held May 13–15 at the Yeosu Expo Convention Center.

KBCS is Korea's largest academic event dedicated to biochip-based diagnostic and analytical technologies, including biochips, bio-MEMS, and biosensors, bringing together researchers and diagnostic experts from academia and industry to share the latest findings. Bioneer focused its promotion on the eco-friendly extraction kit EcoQprep™ Kit and the EcoQprep™ mRNA Kit, which efficiently extracts mRNA — a key element in gene analysis — while also showcasing the automated extraction system ExiPrep™ 96 Lite, the real-time PCR system ExiCycler™ V5, the cell-free protein synthesis system ExiProgen™, related reagents, and its biofoundry's gene synthesis service.

With AI-driven protein structure research booming, ExiProgen™ — which can turn such research into physical reality — and Bioneer's fast-cycling equipment drew strong interest from researchers. Chairman Han-Oh Park was invited to give a talk titled "Bridging the Gap Between AI and Physical Reality Through Biochip Innovation," sharing Bioneer's technical capabilities and vision for accelerating biochip research. The event let Bioneer engage directly with researchers to understand field needs and emerging technology trends, gaining insights for future product development and global market strategy. Bioneer will continue expanding its high-quality research solutions and next-generation biochip technology to meet the demands of the AI era.



Business Updates

CosmeRNA: At WCHR 2026 Seoul, Accelerating Global Push

The CosmeRNA Division took part in the 14th World Congress for Hair Research (WCHR 2026), held May 28–31 at COEX in Seoul. Hosted by the Korean Hair Research Society, WCHR 2026 was the largest edition yet and the most prestigious academic event in hair research, drawing dermatologists, hair specialists, researchers, and global KOLs from around the world. This year's event, held under the slogan "Awakening the Soul of Hair Science," featured wide-ranging academic exchange including the latest hair loss care technologies.

CosmeRNA ran a dedicated booth and engaged in expert networking, presenting its differentiated RNA-technology-based products and communicating directly with the global hair and dermatology professional network about its product features and applications. This connected domestic and international sales activity, KOL communication, and global partnership discussions into a single effort, spreading the word on CosmeRNA's differentiation and further strengthening the foundation for global business growth.

Building on the close connections made with global clinicians, KOLs, and prospective distribution partners at the conference, CosmeRNA plans to expand brand awareness across hospital channels at home and abroad. At the same time, it will diversify overseas distribution channels and move global partnership discussions forward to accelerate global market expansion. The company will also incorporate the feedback and reactions gathered from leading global experts to effectively convey CosmeRNA's differentiated experience and value, continuing to drive brand growth in the global beauty and bio markets.



Business Updates

AceBiome: Wraps Up Vitafoods Europe 2026

AceBiome exhibited at Vitafoods Europe 2026, held May 5–7 in Barcelona, Spain, showcasing key product lines aimed at overseas markets. The exhibit centered on the export version of BNRThin S30, Joint AnaParactin, and BNR Queen, presenting a product portfolio addressing body fat management, joint and bone health, women's health, and skin health.

The show was meaningful as a way to connect AceBiome's functional ingredients and product development capabilities with global market demand. The company presented life-stage health solutions tailored to increasingly specific needs by age, gender, and individual preference, and expanded its touchpoints with buyers and industry contacts across Europe and beyond.

The export version of BNRThin S30 is built on AceBiome's proprietary BNR17® strain, with body-fat-reduction functionality and recently introduced research on muscle health. Amid continued global interest in GLP-1 therapeutics, demand is shifting toward sustainable weight management and healthy lifestyle habits rather than short-term weight loss. BNRThin drew attention in line with this trend as a leading product in the diet probiotics category.

Joint AnaParactin, designed to support both joint and bone health, was presented mainly to middle-aged and older consumers looking to stay active and prepare for healthy aging. BNR Queen was introduced as a multi-functional probiotic tailored for menopausal women, reflecting health needs across women's life stages.

Building on this exhibition, AceBiome plans to expand its functional-product business in global markets including Europe and North America. The company will continue strengthening the competitiveness of its global product portfolio spanning body fat management, joint and bone health, women's health, and skin health.



5-7 May 2026 Barcelona

